Form 6-K — CureVac N.V.: lawsuit in the German Regional Court, intellectual property rights (July 5, 2022)
Summary
A Form 6-K report of foreign private issuer filed by CureVac N.V. with the U.S. Securities and Exchange Commission for the month of July, 2022, Commission File Number 001-39446. It states that on July 5, 2022 the company issued a press release announcing that it has moved to assert intellectual property rights relating to its mRNA technology. According to the report, CureVac has filed a lawsuit in the German Regional Court in Düsseldorf against BioNTech SE and two subsidiaries, seeking fair compensation for infringement of a portfolio of its intellectual property rights, including EP 1 857 122 B1. The press release is Exhibit 99.1, and the information is incorporated into Form F-3, File No. 333-259613.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“Form 6-K — CureVac N.V.: lawsuit in the German Regional Court, intellectual property rights (July 5, 2022).”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-cvac-6-k-filed2022-07-05-0001104659-22-077324-2c48cb3fe0/
, SHA-256 11470eda8605c37562758c9b31ae3de02f445664f0688c7e0f092e6d15316126.Full text
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2022 Commission File Number: 001-39446 CureVac N.V. ( Exact Name of Registrant as Specified in Its Charter ) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F | x | Form 40-F | ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes | ¨ | No | x Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes | ¨ | No | x On July 5, 2022, CureVac N.V. (the “Company”) issued a press release announcing that it has moved to assert intellectual property rights, accumulated over more than two decades of pioneering work in mRNA technology, which contributed to COVID-19 vaccine development. CureVac has filed a lawsuit in the German Regional Court in Düsseldorf against BioNTech SE and two subsidiaries, seeking fair compensation for infringement of a portfolio of its intellectual property rights, EP 1 857 122 B1, DE 20 2015 009 961 U1, DE 20 2021 003 575 U1 and DE 20 2015 009 974 U1, utilized in the manufacture and sale of Comirnaty®, BioNTech and Pfizer’s mRNA COVID-19 vaccine. The information included in this Form 6-K (including Exhibit 99.1) is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-259613). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CUREVAC N.V. By: | /s/ Franz-Werner Haas, LLD, LLM Chief Executive Officer Date: July 5, 2022 EXHIBIT INDEX EXHIBIT NO. | DESCRIPTION 99.1 | CureVac N.V. Press Release dated July 5, 2022.
File and source
- File
- SEC_CVAC_6-K_filed2022-07-05_0001104659-22-077324.htm
- Size
- 13,494 bytes
- SHA-256
- 11470eda8605c37562758c9b31ae3de02f445664f0688c7e0f092e6d15316126
- Original
- www.sec.gov